FAQ on Calidi Biotherapeutics Inc.'s Inducement Stock Option Grant to New CEO Eric Poma

What is the significance of the stock option grant to Calidi Biotherapeutics’ new CEO?

The stock option grant to Eric Poma, Ph.D., signifies Calidi Biotherapeutics’ commitment to attracting and retaining top leadership to advance its clinical-stage biotechnology innovations in targeted antitumor virotherapies.

How many shares are included in the stock option grant to Eric Poma?

The grant includes the option to purchase 726,412 shares of Calidi Biotherapeutics’ common stock.

What is the exercise price of the stock options granted to Eric Poma?

The exercise price is $0.469 per share, which was the closing price of Calidi’s common stock on April 22, 2025.

Over what period will the stock options vest?

The options will vest over four years, with 25% vesting on April 22, 2026, and the remainder vesting in equal monthly installments through April 22, 2029.

What does Calidi Biotherapeutics specialize in?

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer, utilizing novel stem cell-based platforms for delivering oncolytic viruses in oncology indications.

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in San Diego, California.

Where can I find more information about Calidi Biotherapeutics?

For more information, please visit www.calidibio.com or the company’s newsroom at https://ibn.fm/CLDI.

What are the potential benefits of Calidi Biotherapeutics’ technology?

Calidi’s technology is designed to protect, amplify, and potentiate oncolytic viruses, leading to enhanced efficacy and improved patient safety in treating cancer, including high-grade gliomas and solid tumors.